Matches in SemOpenAlex for { <https://semopenalex.org/work/W3137979184> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- W3137979184 endingPage "2" @default.
- W3137979184 startingPage "1" @default.
- W3137979184 abstract "In this memorial lecture, I will review the long drug development history and belated US FDA approval of the adenosine A2A receptor (A2AR) antagonist istradefylline for treatment of Parkinson's disease (PD) and its implications. The A2AR has been long considered as the leading drug target for PD treatment for its highly concentrated expression in the striatopallidal neurons and its colocalization and functional antagonistic interact ion with dopamine D2 receptors in this neuron type. Since the early 1990s, mounting experimental findings have demonstrated the motor enhancement effect of A2AR antagonists, alone or synergizing with L-DOPA in rodents and non-human primates. Since 2001, more than 25 clinical trials were conducted to evaluate the safety and clinical efficacy of A2AR antagonists in PD patients. After more than two decades of preclinical and clinical studies, on August 27, 2019, the U.S. Food and Drug Administration (FDA) approved the adenosine A2A receptor antagonist Nourianz (istradefylline) developed by Kyowa Hakko-Kirin Inc., Japan, as an add-on treatment to levodopa in Parkinson's disease (PD) with OFF episodes. This milestone achievement represent is the first A2AR therapeutic drug and the first non-dopaminergic drug for PD treatment approved by US FDA in the last two decades. This approval provides an important lessons to be remembered, namely the selection of defined patients subpopulations who are most responsive to the tested drug is critical for a successful demonstration of the clinical efficacy of the drug. Importantly, this approval paves the way to foster entirely novel therapeutic opportunities for adenosine A2A receptor antagonists, such as neuroprotection or reversal of mood and cognitive deficits in PD and other neuropsychiatric diseases. As a pioneer, Professor Geoff Burnstock established the purinergic signaling field against all the odds more than 50 years ago and thus set up the stage for us to pursuit and achieve many milestone like this in near future." @default.
- W3137979184 created "2021-03-29" @default.
- W3137979184 creator A5072159453 @default.
- W3137979184 date "2021-01-01" @default.
- W3137979184 modified "2023-10-05" @default.
- W3137979184 title "Adenosine A2A Receptor Antagonists for Parkinson’s Disease Treatment: 18 Years Adventure" @default.
- W3137979184 doi "https://doi.org/10.1254/jpssuppl.94.0_1-s03-2" @default.
- W3137979184 hasPublicationYear "2021" @default.
- W3137979184 type Work @default.
- W3137979184 sameAs 3137979184 @default.
- W3137979184 citedByCount "0" @default.
- W3137979184 crossrefType "journal-article" @default.
- W3137979184 hasAuthorship W3137979184A5072159453 @default.
- W3137979184 hasBestOaLocation W31379791841 @default.
- W3137979184 hasConcept C118552586 @default.
- W3137979184 hasConcept C126322002 @default.
- W3137979184 hasConcept C15744967 @default.
- W3137979184 hasConcept C16568411 @default.
- W3137979184 hasConcept C169760540 @default.
- W3137979184 hasConcept C170493617 @default.
- W3137979184 hasConcept C2778491162 @default.
- W3137979184 hasConcept C2778938600 @default.
- W3137979184 hasConcept C2779134260 @default.
- W3137979184 hasConcept C2779734285 @default.
- W3137979184 hasConcept C2780035454 @default.
- W3137979184 hasConcept C535046627 @default.
- W3137979184 hasConcept C67907053 @default.
- W3137979184 hasConcept C71924100 @default.
- W3137979184 hasConcept C98274493 @default.
- W3137979184 hasConceptScore W3137979184C118552586 @default.
- W3137979184 hasConceptScore W3137979184C126322002 @default.
- W3137979184 hasConceptScore W3137979184C15744967 @default.
- W3137979184 hasConceptScore W3137979184C16568411 @default.
- W3137979184 hasConceptScore W3137979184C169760540 @default.
- W3137979184 hasConceptScore W3137979184C170493617 @default.
- W3137979184 hasConceptScore W3137979184C2778491162 @default.
- W3137979184 hasConceptScore W3137979184C2778938600 @default.
- W3137979184 hasConceptScore W3137979184C2779134260 @default.
- W3137979184 hasConceptScore W3137979184C2779734285 @default.
- W3137979184 hasConceptScore W3137979184C2780035454 @default.
- W3137979184 hasConceptScore W3137979184C535046627 @default.
- W3137979184 hasConceptScore W3137979184C67907053 @default.
- W3137979184 hasConceptScore W3137979184C71924100 @default.
- W3137979184 hasConceptScore W3137979184C98274493 @default.
- W3137979184 hasIssue "0" @default.
- W3137979184 hasLocation W31379791841 @default.
- W3137979184 hasOpenAccess W3137979184 @default.
- W3137979184 hasPrimaryLocation W31379791841 @default.
- W3137979184 hasRelatedWork W1980620322 @default.
- W3137979184 hasRelatedWork W2048664644 @default.
- W3137979184 hasRelatedWork W2062019519 @default.
- W3137979184 hasRelatedWork W2128990320 @default.
- W3137979184 hasRelatedWork W2133965347 @default.
- W3137979184 hasRelatedWork W3021004017 @default.
- W3137979184 hasRelatedWork W3137907604 @default.
- W3137979184 hasRelatedWork W4205517042 @default.
- W3137979184 hasRelatedWork W4224211809 @default.
- W3137979184 hasRelatedWork W4362506662 @default.
- W3137979184 hasVolume "94" @default.
- W3137979184 isParatext "false" @default.
- W3137979184 isRetracted "false" @default.
- W3137979184 magId "3137979184" @default.
- W3137979184 workType "article" @default.